Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Files for Initial Public Offering

NEW YORK, March 1 (GenomeWeb News) - Alnylam Pharmaceuticals has filed a statement with the SEC for an initial public offering, the company said Friday evening.

 

The number of shares of common stock Alnylam plans to offer, and their price, have yet to be determined. Bank of America Securities serves as the company's book-runner and lead manager.

 

Alnylam, based in Cambridge, Mass., plans to develop drugs based on RNA interference.

 

Alnylam would be one of the first companies in the genomics sector in several years to go public: Two years ago, ZymoGenetics raised $120 million in its initial public offering.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.